Search
for
Sort by
Research 271–300 of 375
- Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy: A 24-week prospective observational study
- A clinician’s guide to pediatric and adolescent alopecia areata treatments
- Spironolactone in hidradenitis suppurativa: a single-center
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Performance of an interferon-γ release assay-based test for cell-mediated immunity to SARS-CoV-2
- Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Advances and Perspectives on Bioelectronic and Atomic Nanogenerators for Anticancer Therapy
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- A Quantitative Measurement Method for Nuclear-Pleomorphism Scoring in Breast Cancer
- A retrospective clinical and laboratory analysis including vitamin D and antinuclear antibodies in central centrifugal cicatricial alopecia and nonscarring alopecia in African Americans
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- The prevalence of skin diseases in Greece, impact on quality of life and stigmatization: A population‐based survey study
- Food-derived Crassostrea gigas peptides self-assembled supramolecules for scarless healing
- 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
- The COVID-19 pandemic and its skin effects
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Stimuli-responsive Hydrogels: An Intelligent Tool for Wound Management
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Universal Dermatology: Bridging Gaps in Skin Health
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
- Menopause and hair loss in women: Exploring the hormonal transition
- Patient preferences in the treatment of alopecia areata: A review of the literature
- Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis: Results from a large cross-sectional cohort study
- Biomimetic Scaffolds—A Novel Approach to Three Dimensional Cell Culture Techniques for Potential Implementation in Tissue Engineering
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique